96 related articles for article (PubMed ID: 27456981)
1. Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma [Formula: see text].
Bartholomew J; Washington T; Bergeron S; Nielson D; Saggio J; Quirk L
J Pediatr Oncol Nurs; 2017; 34(1):5-12. PubMed ID: 27456981
[TBL] [Abstract][Full Text] [Related]
2. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
3. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
4. Dinutuximab: A Review in High-Risk Neuroblastoma.
Hoy SM
Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
[TBL] [Abstract][Full Text] [Related]
5. Dinutuximab: first global approval.
Dhillon S
Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
[TBL] [Abstract][Full Text] [Related]
6. Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma.
Garrovillo K; Garrett J; Bollin K; Nasraty F; Sikand H
J Oncol Pharm Pract; 2020 Dec; 26(8):2058-2065. PubMed ID: 32356686
[TBL] [Abstract][Full Text] [Related]
7. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
[TBL] [Abstract][Full Text] [Related]
8. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
9. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
10. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
Greenwood K; Foster JH
Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
[TBL] [Abstract][Full Text] [Related]
11. Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia.
Giljević JS; Rajačić N; Mikulić D; Batoš AT
Children (Basel); 2022 Jun; 9(7):. PubMed ID: 35883927
[TBL] [Abstract][Full Text] [Related]
12. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
13. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of pancreas and gastric carcinoma cell growth by interleukin 3 and granulocyte-macrophage colony-stimulating factor.
Dippold WG; Klingel R; Kerlin M; Schwaeble W; Meyer zum Büschenfelde KH
Gastroenterology; 1991 May; 100(5 Pt 1):1338-44. PubMed ID: 2013378
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
16. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
19. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
[TBL] [Abstract][Full Text] [Related]
20. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
